Celsion Corp.CLSN provided an update on its GEN-1 immunotherapy pipeline. The company said that the first cohort of patients in the phase Ib dose escalating study (OVATION) on GEN-1 plus the standard of care has been completed. The study is being conducted in patients with newly diagnosed ovarian cancer who will undergo neoadjuvant chemotherapy followed by surgical resection of their tumor.
Celsion also said that the first two patients who have completed treatment in the OVATION study, have shown promising results.
The OVATION study will continue this year at higher doses of GEN-1 with the goal of identifying a safe, tolerable and therapeutically active dose.
The optimal dose will be used for a follow-on phase I/II study evaluating GEN-1 plus Avastin and Doxil. Celsion intends to use encouraging pre-clinical data on this combination to support an investigational new drug (IND) filing for a phase I/II study in recurrent ovarian cancer later this year.
We note that Celsion had reported encouraging translational research data from a phase Ib study on GEN-1 in combination with Doxil for the treatment of the patients with platinum-resistant ovarian cancer in Jan 2016.
Celsion is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Actelion Ltd. ALIOF , Anika Therapeutics Inc. ANIK and Atara Biotherapeutics, Inc. ATRA . All three stocks sport a Zacks Rank #1 (Strong Buy).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.